These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36370742)

  • 1. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
    Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
    Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
    Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA
    Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
    Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
    Salamero O; Molero A; Pérez-Simón JA; Arnan M; Coll R; Garcia-Avila S; Acuña-Cruz E; Cano I; Somervaille TCP; Gutierrez S; Arévalo MI; Xaus J; Buesa C; Limón A; Faller DV; Bosch F; Montesinos P
    Lancet Haematol; 2024 Jul; 11(7):e487-e498. PubMed ID: 38824932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
    Wang ES; Issa GC; Erba HP; Altman JK; Montesinos P; DeBotton S; Walter RB; Pettit K; Savona MR; Shah MV; Kremyanskaya M; Baer MR; Foran JM; Schiller G; Adès L; Heiblig M; Berthon C; Peterlin P; Rodríguez-Arbolí E; Salamero O; Patnaik MM; Papayannidis C; Grembecka J; Cierpicki T; Clegg B; Ray J; Linhares BM; Nie K; Mitra A; Ahsan JM; Tabachri M; Soifer HS; Corum D; Leoni M; Dale S; Fathi AT
    Lancet Oncol; 2024 Oct; 25(10):1310-1324. PubMed ID: 39362248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
    Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
    Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
    Daver NG; Montesinos P; DeAngelo DJ; Wang ES; Papadantonakis N; Todisco E; Sweet KL; Pemmaraju N; Lane AA; Torres-Miñana L; Thompson JE; Konopleva MY; Sloss CM; Watkins K; Bedse G; Du Y; Malcolm KE; Zweidler-McKay PA; Kantarjian HM
    Lancet Oncol; 2024 Mar; 25(3):388-399. PubMed ID: 38423051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
    Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
    Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
    Pabst T; Papayannidis C; Demirkan F; Doronin V; Fogliatto LM; Guttke C; Gyan E; Hamad N; Herrera P; Hultberg A; Jacobs J; Johnson AJ; Langlois A; Ma X; Martinelli G; Arnan M; Müller R; Nottage K; Ofran Y; Özcan M; Samoilova O; Tolbert JA; Trudel GC; Xiu L; Vey N; Wei AH
    Lancet Haematol; 2023 Nov; 10(11):e902-e912. PubMed ID: 37914483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
    de Botton S; Fenaux P; Yee K; Récher C; Wei AH; Montesinos P; Taussig DC; Pigneux A; Braun T; Curti A; Grove C; Jonas BA; Khwaja A; Legrand O; Peterlin P; Arnan M; Blum W; Cilloni D; Hiwase DK; Jurcic JG; Krauter J; Thomas X; Watts JM; Yang J; Polyanskaya O; Brevard J; Sweeney J; Barrett E; Cortes J
    Blood Adv; 2023 Jul; 7(13):3117-3127. PubMed ID: 36724515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
    Ohanian M; Tari Ashizawa A; Garcia-Manero G; Pemmaraju N; Kadia T; Jabbour E; Ravandi F; Borthakur G; Andreeff M; Konopleva M; Lim M; Pierce S; O'Brien S; Alvarado Y; Verstovsek S; Wierda W; Kantarjian H; Cortes J
    Lancet Haematol; 2018 Apr; 5(4):e136-e146. PubMed ID: 29550383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.